Emergent BioSolutions Inc
EBS
View Detailed Chart
7.940USD
+0.150+1.93%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
426.38MMarket Cap
3.06P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.93%
5 Days
-3.52%
1 Month
-12.46%
6 Months
+39.54%
Year to Date
-16.95%
1 Year
+15.07%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-18Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Hold
Current Rating
13.500
Target Price
+73.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Overvalued
The company’s latest PE is 2.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.60M shares, decreasing 17.23% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.58M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOMr. Joseph C. (Joe) Papa
Websitehttps://emergentbiosolutions.com/
Related Instruments
+0.37%
-1.72%
+0.53%
-0.80%
-0.15%
+6.27%
+0.48%
+0.41%
+1.21%
+0.42%
+1.51%
-0.01%
-1.19%
-0.30%
-0.15%
-1.70%
-0.03%
+0.12%
+2.26%
+0.10%
